NLRP3 inflammasome Flashcards

1
Q

what is the NLRP3 inflammasome?

A

the NLRP3 inflammasome is a signalling scaffold that coordinates the activation of inflammatory mediators in particular in response to endogenous DAMPs released due to reduction in physical activity, increased consumption of processed foods, aging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

name and describe the three types of Pathogen Recognition receptors?

A
  1. Molecules present in the serum, like C-reactive protein, complement.
  2. Receptors present on cell surface and on endosome - Toll-like Receptors (TLRs)
  3. Intracytoplasmic recognition molecules like NOD-Like receptor (NLR) and RIG-like receptor (RLR)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Name the three components of an inflammasome?

A

a sensor molecule
Adaptor apoptosis-associated speck-like protein containing a CARD (ASC)
effector protease caspase 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what does activation of the sensor molecule result in?

A

ASC self-association into a helical fibrillary assembly leading to the formation of a pyroptosome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

NLRP3 inflammasome acts as molecular scaffold for the activation of _ via proximity induced autocatalytic activation

A

NLRP3 inflammasome acts as molecular scaffold for the activation of procaspase 1 via proximity induced autocatalytic activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what does active caspase 1 trigger the release of?

A

caspase 1 triggers the release of IL-1B and IL-18 (proinflammatory cytokines)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

name the three important domains in the NLRP3 sensor molecule

A

NACHT Domain - has ATPase activity, needed for ATP binding for NLRP3 activation.
Leucine Rich Repeat (LRR) domain - for detection of stimuli, thought to induce autoinhibition by folding back onto NACHT domain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

describe NLRP3 inflammasome assembly and function upon stimulation

A
  1. NLRP3 oligomerizes via NACHT domains
  2. NEK7 (kinase) interacts with NLRP3 and oligomerizes NLRP3 into a complex critical for ASC recruitment
  3. Oligomerized NLRP3 recruits ASC resulting in helical filament formation.
  4. Assembled ASC recruits procaspase 1 through interactions with CARD
  5. Proximity-induced caspase 1 undergoes self cleavage and activation is induced.
  6. caspase 1 cleaves IL-1B and IL-18, these are secreted.
  7. Gasdermin D (GSDMD) is also cleaved by caspase 1 which inserts into the membrane, forms pores and induces pyroptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

the quantity of which NLRP3 inflammasome component is the rate-limiting step of its activation?

A

the quantity of NLRP3 in the cell at rest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is priming

A

the first signal which primes the cell by initiating the transcription of the NLRP3 gene, increasing its expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what receptors need to be engaged for the inflammasome to be primed?

A

pathogen recognition receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what does activation of PRRs lead to

A

Nuclear factor kappa B (NFKB) activation and NLRP3 gene transcription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what effect does priming with LPS have on macrophage metabolism?

A

priming with LPS shifts macrophage metabolism from oxidative phosphorylation to glycolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the second function of priming?

A

the induction of post-translational modifications of NLRP3 which stabilises the NLRP3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Phosphorylation of _ position of LRR domain inhibits NLRP3 activation

A

Y861

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Phosphorylation of _ in NACHT domain by PKA inhibits, while protein kinase D (activates)

A

phosphorylation of S295 in NACHT domain by PKA inhibits while PKD activates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what enzyme do bile acids induce and how does this affect NLRP3 inflammasome

A

bile acids induce PKA which suppresses NLRP3 activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

dephosphorylation at _ inhibits NLRP3 activation by preventing NLRP3 oligomerization and interaction with ASC

A

dephosphorylation at S198 inhibits NLRP3 activation by preventing NLRP3 oligomerisation with ASC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Name some examples of DAMPs

A

ATP, cholesterol crystals, urate crystals, alpha-synuclein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Name some examples of PAMPs

A

LPS, peptidoglycan, Bacterial RNA-DNA hybrid, ssRNA, dsRNA, beta-glucans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Name some examples of PAMPs

A

LPS, peptidoglycan, Bacterial RNA-DNA hybrid, ssRNA, dsRNA, beta-glucans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what are the unifying factors of NLRP3 activators?

A

all induce cellular stress, which is sensed by NLRP3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what are the most commonly accepted activating stimuli for NLRP3

A

K+ Influx through ion channels
cathepsin release following destabilisation of lysosomal membranes
mitochondrial dysfunction (mitochondrial ROS/DNA or cardiolipin)
metabolic changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what are ionophores?

A

bacterial pathogenesis factors - efflux of K+ as a method of sensing presence of bacteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

what is the P2X purinoreceptor

A

high levels of extracellular ATP (due to dying cells in the vicinity of inflammasome-containing cells) result in ion influx via opening of ligand gated ion channel of P2X purinoreceptor - efflux of K+ in addition to Ca2+

26
Q

what bacterial pore-forming toxin activates NLRP3 via K+ influx?

A

streptolysin O

27
Q

what is alum?

A

first discovered adjuvant and most commonly used in vaccines againstt HepB, tetanus, and HPV; induces K+ efflux

28
Q

what causes lysosomal disruption

A

phagocytosis of crystals (cholesterol, uric acid) or protein aggregates (amyloid-beta)

29
Q

what precedes lysosomal swelling and damage?

A

lysosomal acidification

30
Q

what are the cysteine proteases key to lysosomal disruption?

A

cathepsins

31
Q

what are mitochondrial-related ligands for NLRP3?

A

mitochondrial ROS, oxidised mtDNA, phospholipid cardiolipin

32
Q

what is hexokinase 2 function and what does its displacement cause?

A

hexokinase 2 enhances glucose metabolism, displacement of this enzyme from mitochondria trigger increase in mitochondrial Ca2+ causing depolarization and mitochondrial cell death

33
Q

what metabolic change products can activate the inflamasome

A

free fatty acids, palminate,

34
Q

what effect do SCFAs have on NLRP3 Inflammasome activity?

A

they are anti-inflammatory, inhibit priming and activation of NLRP3 inflammmasome by palminate

35
Q

what is the name of the ketone body that inhibits NLRP3 activation

A

beta-hydroxybutyrate

36
Q

what downstream product of NLRP3 activation is inhibited by BHB in murine models of CAPS and in urate crystal model of inflammation?

A

caspase 1 and IL-1B release

37
Q

what is the mechanism behind BHB regulation of NLRP3 inflammasome

A

inhibition of the K+ efflux

38
Q

what is CAPS?

A

Cryopyrin-associated periodic syndromes, group of systemic auto-inflammaotry disorders caused by mutations in the NLRP3 gene. gain of function mutations (spontaneous inflammasome formation in absence of ligand)

39
Q

what interleukin has been found to be elevated in crohn’s disease? what subset of T helper cells does this promote?

A

IL-18, which promotes Th1 response (pathogenic)

40
Q

what do NLRP3 null mice have?

A

increased insulin sensitivity and pancreatic beta cells

41
Q

what are cholesterol crystals associated with?

A

NLRP3-mediated atherosclerosis

42
Q

what are monosodium urate crystals associated with

A

gout flares

43
Q

what are calcium oxalate crystals associated with?

A

kidney dysfunction

44
Q

how do protein aggregates activate the NLRP3 inflammasome?

A

they aggregate and are too large for lysosomal degradation, causing them to accumulate until lysosomal rupture, which subsequently activates NLRP3 inflammasome

45
Q

name drug that blocks IL-1 receptor, its indications, limitation, and administration

A

anakinra, modified IL-1RA, effective for CAPS, RA, short plasma half-life, daily injections required

46
Q

name the drug that inhibits both IL-1B and IL-1a

A

rilonacept, a solubel decoy receptor

47
Q

name the IL-1B neutralising antibody, half life, approved use, administration, BBB penetrative?

A

canakinumab, 26 hour half-life, IV admin, poor BBB penetration

48
Q

direct inhibition of NLRP3 inflammasome activation via?

A

MCC950

49
Q

What kind of drug is MCC950

A

A diarylsulfonylurea small molecule compound

50
Q

what has MCC950 inhibited in human monocytes?

A

ATP-triggered, NLRP3-mediated IL-1B release

51
Q

what preclinical immunopathological models did MCC950 demonstrate therapeutic efficacy against?

A

CAPS, Experimental Autoimmune Encephalitis, Alzheimer disease, atherosclerosis, TBI, cardiac arrhythmias, diabetes, Mi

52
Q

what is the main issue with MCC950 safety profile?

A

hepatotoxicity due to high (1200mg) dose daily

53
Q

what is glyburide typically used for and what are its off-target effect?

A

a T2D drug, potently inhibits NLRP3 activation but requires high doses and MOA is not known, use limited in non-diabetics due to risk of hypoglycaemia

54
Q

what is Dapansutrile (OLT1177)

A

Orally active beta-sulfonyl nitrile molecule that inhibits NLRP3 inflammasome activation

55
Q

what interaction does OLT1177 inhibit?

A

the interaction between ASC and NLRP3

56
Q

what did OLT1177 demonstrate in CAPS patients?

A

reduced IL-1B release in monocytes

57
Q

what did the phase 1 OLT1177 trial exhibit

A

1000mg admin to healthy patients for 8 days showed no biochemical or hematological changes or any adverse effects

58
Q

what did the open-label, proof-of-concept phase 2a trial in adults with monoarticular monosodium urate crystal gout flares show?

A

2000mg for 8 days showed good safety profile, efficacy in reduction of target joint pain

59
Q

name the brain penetrant direct inhibitor

A

inzomelid

60
Q

NLRP3 activation inhibitor for CVD and arthritis?

A

somalix

61
Q

IFM-2427

A

a systemic peripheral NLRP3 antagonist in phase 1 clinical trials for treatment of inflammatory conditions like gout, atherosclerosis and non-alcoholic steatohepatitis

62
Q

DVF890

A

Gut-directed, CNS-penetrant NLRP3 antagonist